Dissecting major signaling pathways in prostate cancer development and progression: Mechanisms and novel therapeutic targets.

Printer-friendly versionPrinter-friendly versionPDF versionPDF version
TitleDissecting major signaling pathways in prostate cancer development and progression: Mechanisms and novel therapeutic targets.
Publication TypeJournal Article
Year of Publication2016
AuthorsSenthilmurugan, R, Ramamurthy, VP, Njar, VCO
JournalJ Steroid Biochem Mol Biol
Date Published2016 Jul 29
ISSN1879-1220
Abstract

Prostate cancer (PCa) is the most frequently diagnosed non-cutaneous malignancy and leading cause of cancer mortality in men. At the initial stages, prostate cancer is dependent upon androgens for their growth and hence effectively combated by androgen deprivation therapy (ADT). However, most patients eventually recur with an androgen deprivation-resistant phenotype, referred to as castration-resistant prostate cancer (CRPC), a more aggressive form for which there is no effective therapy presently available. The current review is an attempt to cover and establish an understanding of some major signaling pathways implicated in prostate cancer developmentand castration-resistance, besides addressing therapeutic strategies that targets thekey signaling mechanisms.

DOI10.1016/j.jsbmb.2016.07.006
Alternate JournalJ. Steroid Biochem. Mol. Biol.
PubMed ID27481707